Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00431015
Status:
COMPLETED
Last Update Posted:
2012-12-10
First Post:
2007-01-31
Brief Title:
Phase III Safety Study of IPI-504 in RelapsedRefractory Stage IIIb or Stage IV Non-small Cell Lung Cancer NSCLC
Sponsor:
Infinity Pharmaceuticals Inc
Organization:
Infinity Pharmaceuticals Inc
Organization Data
Organization:
Infinity Pharmaceuticals Inc
Class:
INDUSTRY
Study ID:
IPI-504-03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Infinity Pharmaceuticals Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None